Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Tang, Xiaoyi ^a   Liu, Ting ^a   Zang, Xuefeng ^a,b   Liu, Hao ^a   Wang, Danhong ^a   Chen, Hu ^a   Zhang, Bin ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CIMETIDINE; INTERLEUKIN 2;

ADOPTIVE CELLULAR IMMUNOTHERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; APNEA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DYSPNEA; EMBOLISM; FEMALE; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LUNG TOXICITY; LYMPHOCYTE TRANSFER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84877129770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062847     Document Type: Review

References (26)

1. Palucka K, Banchereau J, (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277.
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
4. Armstrong AC, Eaton D, Ewing JC, (2001) Science, medicine, and the future: Cellular immunotherapy for cancer. BMJ 323: 1289-1293.
5. Okur FV, Brenner MK, et al. (2010) Cellular immunotherapy of cancer. In: Yotnda P, editor. Immunotherapy of Cancer: Methods and Protocols. New York: Humana Press/Springer Science+Business Media. 319-345.
6. Märten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, et al. (2001) Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86: 1029-1037.
7. Fu GF, Chen X, Hu HY, Yang HT, Xu XQ, et al. (2012) Emergence of peripheral CD3+CD56+ cytokine-induced killer cell in HIV-1-infected Chinese children. Int Immunol 24: 197-206.
8. Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M, et al. (2011) Is adoptive T-cell therapy for solid tumors coming of age? Bone Marrow Transplant 47: 1013-1019.
9. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, et al. (1990) Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335: 994-998.
10. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, et al. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76: 824-832.
11. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, et al. (1999) Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17: 2521-2529.
12. Liu L, Zhang W, Qi X, Li H, Yu J, et al. (2012) Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 18: 1751-1759.
13. Thurnher M, Putz T, Rahm A, Gander H, Ramoner R, et al. (2006) Renal cell carcinoma. In: Lutz MB, Romani N, Steinkasserer A, editors. Handbook of dendritic cells. Weinheim: WILEY-VCH Verlag GmbH & Co. KG Aa. 1155-1156.
14. Itsumi M, Tatsugami K (2010) Immunotherapy for renal cell carcinoma. Clin Dev Immunol 284581.
15. Rini BI, Campbell SC, Escudier B, (2009) Renal cell carcinoma. Lancet 373: 1119-1132.
16. Ranieri E, Gigante M, Storkus WJ, Gesualdo L, (2007) Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 147: 395-400.
17. Shablak A, Hawkins RE, Rothwell DG, Elkord E, (2009) T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective. Clin Cancer Res 15: 6503-6510.
18. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 25: CD001425.
19. Porter DL, Levine BL, Kalos M, Bagg A, June CH, (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
20. Xie F, Zhang X, Li H, Zheng T, Xu F, et al. (2012) Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One 7: e42879.
21. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
22. June C, Rosenberg SA, Sadelain M, Weber JS, (2012) T-cell therapy at the threshold. Nat Biotechnol 30: 611-614.
23. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, et al. (2011) White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17: 1664-1673.
24. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, et al. (2010) Improved Endpoints for Cancer Immunotherapy Trials. J Natl Cancer Inst 102: 1388-1397.
25. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420.
26. Restifo NP, Dudley ME, Rosenberg SA, (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.